Page 65 - Read Online

Biophys Res Commun 2005;333:328-35. N, Wu MF, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ahmed N,
33. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Gottschalk S. T cells redirected to EphA2 for the immunotherapy of
Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan glioblastoma. Mol Ther 2013;21:629-37.
S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman 44. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC,
AH, Friedman HS. Bevacizumab plus irinotecan in recurrent Naranjo A, Star R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler
glioblastoma multiforme. J Clin Oncol 2007;25:4722-9. JA, Portnow J, D’Apuzzo M, Forman SJ, Jensen MC. Bioactivity and
34. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+
receptor variant III (EGFRvIII): where wild things are altered. T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res
FEBS J 2013;280:5350-70. 2015;21:4062-72.
35. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, 45. Sharma P, Allison JP. The future of immune checkpoint therapy.
Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS. Cetuximab, Science 2015;348:56-61.
bevacizumab, and irinotecan for patients with primary glioblastoma 46. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C,
and progression after radiation therapy and temozolomide: a phase II Nicholas S, Kellett M, Ruzevick J, Jackson C, Albesiano E, Durham
trial. Neuro Oncol 2010;12:508-16. NM, Ye X, Tran PT, Tyler B, Wong JW, Brem H, Pardoll DM, Drake
36. Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, CG, Lim M. Focal radiation therapy combined with 4-1BB activation
Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, and CTLA-4 blockade yields long-term survival and a protective
Chen Q, Hill JS, Fanslow WC. AMG 595, an Anti-EGFRvIII Antibody- antigen-specific memory response in a murine glioma model. PLoS
Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII- One 2014;9:e101764.
Expressing Glioblastoma. Mol Cancer Ther 2015;14:1614-24. 47. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias
37. Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, A, Cheng Y, Kim JW, Qiao J, Zhang L, Han Y, Lesniak MS. Durable
Firat E, Klingner K, Schüler J, Wider D, Wäsch RM, Herold-Mende C, therapeutic efficacy utilizing combinatorial blockade against IDO,
Elsässer-Beile U, Niedermann G. Effective Eradication of Glioblastoma CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res
Stem Cells by Local Application of an AC133/CD133-Specific T-cell- 2014;20:5290-301.
Engaging Antibody and CD8 T Cells. Cancer Res 2015;75:2166-76. 48. Baek SK, Makkouk AR, Krasieva T, Sun CH, Madsen SJ, Hirschberg
38. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker H. Photothermaltreatment of glioma; an in vitro study of macrophage-
M, Oefne PJ, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier mediateddelivery of gold nanoshells. J Neurooncol 2011;104:439-48.
CP. Transcriptional profiles of CD133+ and CD133- glioblastoma- 49. Gras Navarro A, Kmiecik J, Leiss L, Zelkowski M, Engelsen A,
derived cancer stem celllinessuggestdifferentcells of origin. Cancer Res Bruserud Ø, Zimmer J, Enger PØ, Chekenya M. NK cells with
2010;70:2030-40. KIR2DS2 immunogenotype have a functional activation advantage
39. Brescia P, Richichi C, Pelicci G. Currentstrategies for identification to efficiently kill glioblastoma and prolong animal survival. J Immunol
of glioma stem cells: adequate or unsatisfactory? J Oncol 2014;193:6192-206.
2012;2012:376894. 50. Hoa NT, Ge L, Erickson KL, Kruse CA, Cornforth AN, Kuznetsov Y,
40. Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, McPherson A, Martini F, Jadus MR. Fascin-1 knock-down of human
Li S. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune glioma cells reduces their microvilli/filopodia while improving their
Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst susceptibility to lymphocyte-mediated cytotoxicity. Am J Transl Res
2015;107. 2015;7:271-84.
41. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, 51. Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, M Nettlebeck
Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, D, Han Y, Zhang L, Lesniak MS. Intratumoral oncolytic adenoviral
Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell treatment modulates the glioma microenvironment and facilitates
T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, systemic tumor-antigen-specific T cell therapy. Oncoimmunology
Okada H, June CH, Brogdon JL, Maus MV. Rational development and 2015;4:e1022302.
characterization of humanized anti-EGFR variant III chimeric antigen 52. Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties
receptor T cells for glioblastoma. Sci Transl Med 2015;7:275ra22. of ionizing radiation: rationale for the treatment of cancer by
42. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel combination radiotherapy and immune checkpoint inhibitors. Cancer
molecular marker and target in glioblastoma multiforme. Mol Cancer Immunol Immunother doi: 10.1007/s00262-015-1771-8.
Res 2005;3:541-51. 53. Assimakopoulos A, Polyzoidis K, Kyritsis AP. Stem cells in gliomas. J
43. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso Stem Cells Res Rev & Rep 2014;1:1009.

56 Neuroimmunol Neuroinflammation | Volume 3 | March 14, 2016